Posted by Michael Wonder on 25 Apr 2022
Sol-Gel Technologies and Galderma Announce FDA approval of Epsolay
25 April 2022 - Epsolay (5% benzoyl peroxide topical cream) utilises Sol-Gel’s proprietary microencapsulation technology for the treatment of inflammatory lesions of rosacea and is patent protected until 2040.
Sol-Gel Technologies announced today the FDA approval of its drug product, Epsolay, a proprietary cream formulation of benzoyl peroxide, 5%, for the treatment of inflammatory lesions of rosacea in adults.
